CDH Investments

CDH Investments is one of China’s oldest and most established alternative asset managers, with a Beijing headquarters and a history that includes large-scale pharmaceutical buyouts and the scaling of comprehensive clinical infrastructure businesses. Within healthcare, the firm focuses on pharma and therapeutics alongside care delivery and tech-enabled services at Series C and growth stage. CDH operates across private equity, venture, and broader alternatives, and the healthcare practice draws on the firm’s institutional depth in deal structuring, governance, and post-investment value creation. Limited public information about specific healthcare-focused partners and current investment cycle priorities is available in English-language sources, though the firm’s institutional profile is well established.

Check sizes start at 25 million dollars and scale upward, deployed at Series C and growth stages into companies with proven commercial traction or clear consolidation roles within their sub-sectors. Geography centers on China with Beijing as the base, and the firm’s reach extends across major Chinese healthcare hubs and into selective cross-border opportunities. Earlier-stage founders will not be a fit for this mandate.

Founders engaging CDH should expect a private-equity-style process: detailed financial diligence, structured term sheets, board governance, and clear value-creation plans. The right candidates are scaled pharma or healthcare services businesses with the operational maturity to absorb significant capital and the strategic positioning to benefit from a major institutional partner. Companies still in commercial validation should look elsewhere. Initial conversations should focus on the company’s strategic positioning, the structure CDH would propose, and how governance and operational support are typically configured for deals at this scale.